Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PPARγ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1
Patricia C. Chui, Hong-Ping Guan, Michael Lehrke, Mitchell A. Lazar
Patricia C. Chui, Hong-Ping Guan, Michael Lehrke, Mitchell A. Lazar
View: Text | PDF
Research Article Metabolism

PPARγ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1

  • Text
  • PDF
Abstract

In addition to its role in energy storage, adipose tissue also accumulates cholesterol. Concentrations of cholesterol and triglycerides are strongly correlated in the adipocyte, but little is known about mechanisms regulating cholesterol metabolism in fat cells. Here we report that antidiabetic thiazolidinediones (TZDs) and other ligands for the nuclear receptor PPARγ dramatically upregulate oxidized LDL receptor 1 (OLR1) in adipocytes by facilitating the exchange of coactivators for corepressors on the OLR1 gene in cultured mouse adipocytes. TZDs markedly stimulate the uptake of oxidized LDL (oxLDL) into adipocytes, and this requires OLR1. Increased OLR1 expression, resulting either from TZD treatment or adenoviral gene delivery, significantly augments adipocyte cholesterol content and enhances fatty acid uptake. OLR1 expression in white adipose tissue is increased in obesity and is further induced by PPARγ ligand treatment in vivo. Serum oxLDL levels are decreased in both lean and obese diabetic animals treated with TZDs. These data identify OLR1 as a novel PPARγ target gene in adipocytes. While the physiological role of adipose tissue in cholesterol and oxLDL metabolism remains to be established, the induction of OLR1 is a potential means by which PPARγ ligands regulate lipid metabolism and insulin sensitivity in adipocytes.

Authors

Patricia C. Chui, Hong-Ping Guan, Michael Lehrke, Mitchell A. Lazar

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
OLR1
 is induced by PPARγ ligands in 3T3 L1 adipocytes. (A) Comparison o...
OLR1 is induced by PPARγ ligands in 3T3 L1 adipocytes. (A) Comparison of OLR1 and aP2 mRNA levels in 3T3-L1 preadipocytes (Pread), adipocytes treated with vehicle (DMSO), and rosiglitazone-treated adipocytes (Rosi). (B) Quantitation of OLR1 compared with CD36 mRNA induction by rosiglitazone, using real-time PCR. Results are normalized to mRNA levels in vehicle-treated adipocytes. Data expressed as mean ± SEM (n = 4). (C) Rosiglitazone induces OLR1 protein expression in 3T3-L1 adipocytes according to Western blot analysis. Histone deacetylase 2 (HDAC2) protein levels show equal loading. (D) Rosiglitazone (500 nM or 1 μM for 4 days) induces OLR1 mRNA expression in human adipocytes. Real-time PCR results expressed as mean ± SEM (n = 4). hOLR1, human OLR1. (E) Dose response for OLR1 induction by rosiglitazone and the non-TZD PPARγ ligand GW7845. (F) Induction of OLR1 by rosiglitazone (100 nM) is blocked by the PPARγ antagonist PD068235 (PD; 50 μM). rRNA, ribosomal RNA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts